Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-011121

PRESIDENT AND CEO sold 5,000 shares at $16.42 ($82,096)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-04-17 Sale : show line 1 in the form 10b5-1 −5,000 $16.42 $82,096 985,392 I
Open-market sales · 5,000 sh · avg $16.42 · $82,096
Loading xslF345X05/form4-04212025_090428.xml…